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therapy robustly revascularizes ischemic myocardium and
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1090Objectives: Cell-based angiogenic therapy for ischemic heart failure has had limited clinical impact, likely
related to low cell retention (<1%) and dispersion. We developed a novel, tissue-engineered, hydrogel-based
cell-delivery strategy to overcome these limitations and provide prolonged regional retention of myocardial
endothelial progenitor cells at high cell dosage.
Methods: Endothelial progenitor cellswere isolated fromWistar rats andencapsulated infibringels. Invitroviability
was quantified using a fluorescent live-dead stain of transgenic enhanced green fluorescent proteinþ endothelial pro-
genitor cells. Endothelial progenitor cell-laden constructs were implanted onto ischemic rat myocardium in a model
of acutemyocardial infarction (left anterior descending ligation) for 4weeks. Intramyocardial cell injection (23 106
endothelial progenitor cells), empty fibrin, and isolated left anterior descending ligation groups served as controls.
Hemodynamics were quantified using echocardiography, Doppler flow analysis, and intraventricular pressure-
volume analysis. Vasculogenesis and ventricular geometry were quantified. Endothelial progenitor cell migration
was analyzed by using endothelial progenitor cells from transgenic enhanced green fluorescent proteinþ rodents.
Results: Endothelial progenitor cells demonstrated an overall 88.7% viability for all matrix and cell conditions
investigated after 48 hours. Histologic assessment of 1-week implants demonstrated significant migration of
transgenic enhanced green fluorescent proteinþ endothelial progenitor cells from the fibrin matrix to
the infarcted myocardium compared with intramyocardial cell injection (28  12.3 cells/high power field vs
2.4  2.1 cells/high power field, P ¼ .0001). We also observed a marked increase in vasculogenesis at the
implant site. Significant improvements in ventricular hemodynamics and geometry were present after endothe-
lial progenitor cell-hydrogel therapy compared with control.
Conclusions: We present a tissue-engineered, hydrogel-based endothelial progenitor cell-mediated therapy
to enhance cell delivery, cell retention, vasculogenesis, and preservation of myocardial structure and function.
(J Thorac Cardiovasc Surg 2014;148:1090-8)Ischemic heart failure is a major global health concern.
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The Journal of Thoracic and Cardiovascular Sursuccessfully reduce mortality from acute myocardial
infarctions, the progression to ischemic heart failure has
not been ameliorated.1-3 The concept of postnatal
vasculogenesis has been widely investigated for
molecular therapy to revascularize ischemic myocardium.
Endothelial progenitor cells (EPCs) are pluripotent, bone
marrow–derived stem cells with the ability to differentiate
into de novo vasculature. Initial enthusiasm was focused
on genetic and cytokine therapy to locally recruit EPCs to
ischemic myocardium. Subsequent studies have attempted
to use cell therapy to directly deliver EPCs locally to the
myocardium. Although significant neovasculogenic
responses have been seen in small and large animal
trials, this benefit has not been translatable to the clinical
setting.
Much concern has been raised about cell delivery,
dispersal, and engraftment. Cell tracking has demonstrated
that less than 1% of cells remain after direct myocardial in-
jection.4-7 We propose a novel therapy, whereby engineered
fibrin gel constructs encapsulating EPCs can overcomegery c September 2014
Abbreviations and Acronyms
DAPI ¼ 40,6-diamidino-2-phenylindole
eGFP ¼ enhanced green fluorescent protein
EPC ¼ endothelial progenitor cell
FITC ¼ fluorescein isothiocyanate
hpf ¼ high power field
LAD ¼ left anterior descending
PBS ¼ phosphate-buffered saline
SMA ¼ smooth muscle actin
Atluri et al Evolving Technology/Basic Sciencethese limitations by providing an environment in which the
cells can thrive, enabling an insult-free delivery to ischemic
myocardium in high cellular concentration for a prolonged
period. In this strategy, EPCs are thought to promote neo-
vasculogenesis by primarily forming de novo vasculature.
In addition, EPCs demonstrate paracrine capabilities by
eluting proangiogenic cytokines that induce vessel growth
by promoting the migration and proliferation of circulating
endothelial progenitor/precursor cells.8,9 Hydrogels are
biocompatible materials capable of providing the
microenvironment necessary to allow cell viability and
migration to ischemic myocardium after delivery. Fibrin,
once polymerized by thrombin, is a particularly attractive
biogel that is part of the normal hemostatic pathway and
thus is entirely biocompatible. It is already approved for
clinical use, thereby facilitating rapid clinical
translatability of this therapy. We hypothesize that
engineered gels seeded with EPCs at high cellular density
will allow high cellular retention rates with direct
migration of a large proportion of stem cells to ischemic
myocardium.E
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Animal Care and Biosafety
Male adult Wistar rats (250-300 g) were obtained from Charles River
Laboratories (Boston, Mass). Food and water were provided ad libitum.
This investigation adheres to theGuide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (8th ed, revised
2011). This study conforms to institutional ethical review and has been
approved by the University of Pennsylvania Institutional Animal Care
and Use Committee. All measurements were performed by investigators
blinded to animal treatment.TABLE 1. In vitro endothelial progenitor cell viability within endothelial
Construct composition Day 2
5 mg/mL fibrin 7 3 106 cells/mL 85.9%  3.2%
5 mg/mL fibrin 17 3 106 cells/mL 80.8%  4.7%
10 mg/mL fibrin 7 3 106 cells/mL 89.1%  2.3%
10 mg/mL fibrin 17 3 106 cells/mL 85.2%  3.6%
20 mg/mL fibrin 7 3 106 cells/mL 90.3%  2.9%
20 mg/mL fibrin 17 3 106 cells/mL 88.3%  3.7%
Viability is demonstrated as percent live cells compared with overall cell density (n ¼ 6/g
The Journal of Thoracic and CarEndothelial Progenitor Cell Isolation
Bone marrow mononuclear cells were isolated from the long bones of
syngeneic adult, male Wistar rats by density-gradient centrifugation (Histo-
paque 1083; Sigma, St Louis,Mo). After isolation, the cellswere seeded on a
vitronectin-coated dish. The cells were cultured in endothelial basal
medium-2 supplemented with EGM-2 singlequot containing human
epidermal growth factor, fetal bovine serum, vascular endothelial growth
factor, human fibroblast growth factor-B, R3-insulin-like growth factor I, as-
corbic acid, heparin, gentamicin, and amphotericin-B for 6 days (Lonza,
Basel, Switzerland). A subset of EPCs were isolated from transgenic rats
ubiquitously expressing enhanced green fluorescent protein (eGFP), with a
2-point mutation to enhance spectral characteristics, fluorescence, and sta-
bility,whichwemade useof for cell fate trackingpurposes. The eGFPcolony
was prepared from eGFP transgene (cDNA fragment of eGFP derived from
phosphorylated eGFP vector No. 6077-1, Clontech Laboratories [Mountain
View, Calif], and pCXN2 expression vector containing cytomegalovirus
enhancer, chicken b-actin enhancer–promoter, and rabbit b-globin poly(A)
signal), obtained from Dr Kobayashi, Jichi Medical School, Tochigi,
Japan.10 EPCphenotype (DiLDLþVEGFR2þCD34þ) was confirmedas pre-
viously published by our group.11,12
Endothelial Progenitor Cell Fibrin Hydrogel
Construct Creation
To form the 20mg/mL fibrin gels, 5.32mgof fibrinogen (Sigma, St Louis,
Mo) was added to phosphate-buffered saline (PBS) and added to the appro-
priate quantity of EPCs for a final volume of 266 mL. To manufacture the
10 mg/mL fibrin gels, 2.66 mg of Fibrinogen (Sigma) was added to PBS
and added to the appropriate quantity of EPCs for a final volume of
266 mL. After preparation of the fibrinogen and EPC mixture in PBS, this
266 mL of mixture was mixed into 0.333 Units of thrombin (Sigma);
100 mL of this liquid mixture was pipetted directly onto the center of a rect-
angular piece ofVicrylmesh (153 12mm) to provide integrity for implant.
In Vitro Analysis of Endothelial Progenitor Cell
Migration and Viability Within the Construct
To assess the viability of EPCs embedded into fibrin-derived gels, EPCs
were embedded into fibrin-derived gels as described earlier. After gel prep-
aration, the LIVE/DEADViability/Cytotoxicity Kit (Invitrogen, Carlsbad,
Calif) was used to determine the percentage of viable EPCs, according to
manufacturer instructions. Samples were visualized on a DF5000B Leica
fluorescent microscope and analyzed using LASAF version 2.0.2 software
(Leica, Wetzlar, Germany).
Induction of Heart Failure
Male Wistar rats were anesthetized in an induction chamber (VetEquip;
Ethicon, Blue Ash, Ohio) with 3% isofluorane, endotracheally intubated,
and mechanically ventilated (Hallowell EMC; Ethicon) with 1.0% isoflur-
ane. A left fourth interspace thoracotomy was performed, and the left ante-
rior descending (LAD) coronary artery was ligated with a 7-0 Prolene
suture at the level of the left atrial appendage. This induced a consistent
and reproducible anterolateral infarction of 35% to 40% of the leftprogenitor cell-fibrin hydrogel constructs
Day 6 Day 10
65.2%  8.5% 48.7%  1.8%
71.9%  6.1% 56.9%  3.5%
61.3%  5.6% 44.8%  5.3%
59.5%  3.7% 66.0%  5.8%
63.7%  5.4% 45.4%  4.8%
73.5%  2.8% 55.0%  4.2%
roup).
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FIGURE 1. EPCs demonstrate characteristic spreading, in vitro, within
the EPC fibrin hydrogel construct 2 days after construct (10 mg/mL fibrin,
17 3 106 EPCs/mL) creation (eGFPþ EPCs, confocal microscopy, 203
magnification).
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Sventricle.12-17 After LAD ligation, the animals were randomized to 1 of 8
groups: control (coronary ligation alone), implant of a fibrin patch without
cells (10 mg/mL [FIB 10] or 20 mg/mL [FIB 20]), injection of EPCs (IC, 2
million cells/in 250 mL PBS), or implant of EPC-fibrin hydrogel (10 mg/
mL fibrin 7 3 106 EPCs/mL, 10 mg/mL fibrin 17 3 106 EPCs/mL, 20
mg/mL fibrin 7 3 106 EPCs/mL, 20 mg/mL fibrin 17 3 106 EPCs/mL).
The constructs were sutured in place with a 7-0 Prolene suture over theFIGURE 2. Immunofluorescent imaging of eGFPþ transgenic EPCs migratio
stained for nuclei (DAPI, blue), eGFP (green), and a-SMA (red) (203 magnifi
enhanced green fluorescent protein; SMA, smooth muscle actin; IC, injection o
1092 The Journal of Thoracic and Cardiovascular Surarea of myocardial injury with the cellular surface facing the myocardium.
The thoracotomy was closed in 3 layers, and the animals were allowed to
recover. Four weeks after myocardial infarction, the animals were sacri-
ficed after hemodynamic analysis for histologic analysis.
Confirmation of Endothelial Progenitor Cell
Migration Into the Myocardium
Our first step, in vivo, was to establish that EPCs from the construct
had the ability to migrate from the construct into the myocardium. To
assess EPC migration, eGFPþ EPCs from transgenic rats were used to
create the construct (20 mg/mL fibrin, 17 3 106 EPCs/mL). This
construct was then implanted onto ischemic myocardium after LAD liga-
tion. The hearts were explanted 1 week after implant, flushed with PBS,
and distended with optical cutting temperature embedding compound
(Electron Microscopy Sciences, Hatfield, Pa). Visualization was per-
formed in the peri-infarct border zone, which was defined as 1 micro-
scopic field from the infarct. Hearts treated with construct were
compared with IC. Sections were briefly washed, fixed in 4% parafor-
maldehyde, and stained for anti-GFP and anti-a smooth muscle actin
(SMA, pericytes). Primary antibodies used for indirect immunofluores-
cence were goat anti-GFP (1:200, Rockland, Gilbertsville, Pa) and rabbit
anti-SMA (1:150, Abcam, Cambridge, England). Secondary antibodies
included donkey anti-goat conjugated to fluorescein isothiocyanate
(FITC) (1:200, Abcam) and donkey anti-rabbit conjugated to Alexa Fluor
594 (1:200, Abcam). Nuclei were counterstained with 40,6-diamidino-2-
phenylindole (DAPI) (Vector Laboratories, Burlingame, Calif). Construct
was compared with control (isolated LAD ligation) and IC.
Quantification of Myocardial Vasculogenesis
Sections were briefly washed 3 times in PBS, fixed in 4% paraformal-
dehyde for 10 minutes at room temperature, and blocked in 10% fetal
bovine serum (Gibco) for 1 hour at 37C. Primary antibodies were diluted
1:150 in PBS and incubated for 2 hours at 37C. Secondary antibodies were
diluted in PBS and incubated for 1 hour at 37C. Primary antibodies
included sheep anti–von Willebrand factor (endothelial cells ofn from the EPC-fibrin construct to the myocardium. Sections were triple
cation, scale bar ¼ 75 mm). DAPI, 40,6-diamidino-2-phenylindole; eGFP,
f EPCs.
gery c September 2014
FIGURE 3. Quantification of myocardial neovasculogenesis within the ischemic peri-infarct myocardium. EPC, Endothelial progenitor cell; hpf, high
power field; IC, injection of EPCs; FIB, fibrin patch without cells.
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Secondary antibodies (1:200) were donkey anti-goat conjugated to FITC
(Abcam), and donkey anti-rabbit conjugated to Alexa Fluor 594 (Abcam).
Nuclei were stained with DAPI (Vector Laboratories). Vasculature was
quantified using ImageJ (National Institutes of Health, Bethesda, Md).
Measurements were made 1 high power field (hpf) from the infarct at
203 magnification.
Analysis of Myocardial Fibrosis
Hearts were explanted from animals, flushed with PBS, and distended
with Tissue Tek (Sakura Finetek USA Inc, Torrance, Calif) optimum cut-
ting temperature compound. Hearts were then submerged in optimum
cutting temperature and frozen at 80C; 10-mm–thick sections were
prepared from each heart using a cryostat at the level of the mid-
papillary muscles. Masson’s trichrome stain was performed on the sec-
tions using the Accustain Trichrome Stains Kit (Sigma) according to
the manufacturer’s instructions. Stained slides were scanned and images
were analyzed in ImageJ (National Institutes of Health) to assess scar
fraction.The Journal of Thoracic and CarAnalysis of Global Ventricular Function
Before explanting the heart, transthoracic echocardiography was per-
formed to assess myocardial function (Phillips [Andover, Mass] Sonos
5500 revD system with an S12 probe at 12 MHz and a 3-cm depth of pene-
tration). Ventricular measurements were performed according to the Amer-
ican Society for Echocardiography leading-edge method. Subsequently, A
2F pressure-volume catheter (Millar Instruments, Houston, Tex) was in-
serted into the left ventricle retrograde via the right common carotid artery
for analysis of left ventricular function. In addition to steady-state hemody-
namic parameters, contractility was determined from pressure-volume rela-
tionships obtained by reducing preload via occlusion of the inferior vena
cava. After echocardiographic and pressure-volume analysis, a midline ster-
notomywas performed and a 2.5-mmascending aortic flowprobe (Transonic
Systems Inc, Ithaca, NY) was placed for Doppler analysis of cardiac output.
Statistical Analysis
Quantitative data are expressed as means  standard error of the mean.
Statistical significance was evaluated using the unpaired Student t test for
comparison between 2 means.diovascular Surgery c Volume 148, Number 3 1093
FIGURE4. Representative immunofluorescent images demonstrating vascular density in peri-infarct ischemicmyocardium after therapy (203magnification;
green ¼ von Willebrand factor, blue ¼ DAPI, red ¼ aSMA). EPC, Endothelial progenitor cell; IC, injection of EPCs; FIB, fibrin patch without cells.
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Endothelial Progenitor Cells Remain Viable Within
the Engineered Fibrin Construct
To ensure viability of EPCs within the fibrin hydrogel
construct, in vitro, live-dead stain was analyzed. Quantifica-
tion of viability revealed significant viability of EPCs
within the construct at 2 days (Table 1). Lower viability
was noted with prolonged time. Excellent viability was
noted to 10 days after implant in the construct, in vitro.
Confocal imaging demonstrated characteristic EPC
spreading and migration by 2 days within the construct
(Figure 1).Robust Endothelial Progenitor Cell Migration From
the Construct to Ischemic Myocardium
Establishing migratory potential of eGFPþ EPCs from
the engineered EPC fibrin construct to the ischemic
myocardium helps to determine the vasculogenic potential
of this therapy. Immunofluorescent microscopy demon-
strated a marked number of EPCs within the deep myocar-
dium, indicating significant migration of EPCs from the
construct. When compared with control, a statistically sig-
nificant number of EPCs were noted within the deepTABLE 2. Left ventricular myocardial scar fraction 4 weeks after left ant
Left ventricu
Control (n ¼ 7) 13.0% 
IC (n ¼ 6) 8.2% 
FIB 10 (n ¼ 13) 11.7% 
FIB 20 (n ¼ 16) 12.3% 
10 mg/mL fibrin with 7 3 106 EPCs/mL (n ¼ 11) 6.2% 
10 mg/mL fibrin with 17 3 106 EPCs/mL (n ¼ 8) 5.0% 
20 mg/mL fibrin with 7 3 106 EPCs/mL (n ¼ 14) 5.0% 
20 mg/mL fibrin with 17 3 106 EPCs/mL (n ¼ 10) 4.0% 
EPC, Endothelial progenitor cell; IC, injection of EPCs; FIB, fibrin patch without cells.
1094 The Journal of Thoracic and Cardiovascular Surmyocardium (28.5  12.3 cells/hpf vs 0 cells/hpf, n ¼ 5/
group, P< .00001). In addition, when compared with IC
there was a markedly increased number of delivered EPCs
within the myocardium (28  12.3 cells/hpf vs 2.4  2.1
cells/hpf, n ¼ 6/group, P ¼ .0001), denoting enhanced
delivery efficiency with the construct compared with IC
(Figure 2).Tissue-Engineered Endothelial Progenitor
Cell–Fibrin Hydrogel Construct Implant Enhances
Myocardial Vasculogenesis
Quantification of myocardial vasculogenesis demon-
strated a statistically significant increase in neovasculogen-
esis within the ischemic myocardium after treatment with
all 4 EPC fibrin constructs when compared with control
(Figure 3). Furthermore, all 4 construct treatment groups
had a statistically significant increase in neovasculogenesis
when compared with IC. This demonstrates that enhanced
cell retention may contribute to enhanced vasculogenesis.
Of note, the isolated, empty fibrin gels (FIB 10 and FIB
20) also demonstrated increased vascular density when
compared with control. The construct with the high cell
and high density (20 mg/mL fibrin 17 3 106 EPCs/mL)erior descending coronary artery ligation and treatment
lar infarct P vs control P vs cell injection (IC)
5.5% .0009
3.0% .0009
5.6% .6 .00006
11.8% .5 .0002
3.7% .02 .002
2.9% .009 .002
3.6% .008 .0002
3.3% .004 .02
gery c September 2014
FIGURE 5. Representative myocardial cross-sectional images after Masson’s trichrome staining to delineate myocardial scar (scar ¼ blue,
myocardium ¼ red). EPC, Endothelial progenitor cell; IC, injection of EPCs; FIB, fibrin patch without cells.
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genesis when compared with the 20 mg/mL fibrin 7 3 106
EPC/mL (P ¼ .02), 10 mg/mL fibrin 7 3 106 EPC/mL
(P ¼ .001), and 10 mg/mL fibrin 17 3 106 EPC/mL
(P ¼ .04). Both 20 mg/mL fibrin 7 3 106 EPC/mL and 10
mg/mL fibrin 7 3 106 EPC/mL hydrogels demonstrated a
significantly increased vasculogenic potential when
compared with the low-density, low-cell construct (10
mg/mL fibrin 7 3 106 EPC/mL) (P ¼ .02 and .05, respec-
tively). There was no statistically significant difference in
vasculogenesis between 20 mg/mL fibrin 7 3 106 EPC/
mL and 10 mg/mL fibrin 7 3 106 EPC/mL constructs
(P ¼ .9) (Figure 4).
Endothelial Progenitor Cell Fibrin Construct
Implants Minimize Myocardial Fibrosis
A marked reduction in myocardial fibrosis and ventricu-
lar scar was demonstrated with treatment with all 4
construct groups when compared with control (Table 2).
Moreover, IC demonstrated a significant reduction in scar
fraction when compared with control (P ¼ .0009). There
was no significant difference in scar formation between iso-
lated fibrin gel implant (FIB 10 or FIB 20) and control. All 4
construct groups demonstrated a statistically significant
reduction in scar formation when compared with IC. There
was no significant difference in scar fraction between the 4
EPC-fibrin hydrogel construct groups (Figure 5).
Endothelial Progenitor Cell Fibrin Construct
Implant Markedly Improves Myocardial Function
Hemodynamic analysis demonstrated a statistically sig-
nificant improvement in cardiac output, ejection fraction,The Journal of Thoracic and Carcontractility, dP/dT max, and maximum generated pressure
for all EPC-fibrin constructs when compared with IC and
control (Table 3). There was no significant difference in he-
modynamic function as measured by these parameters be-
tween the treatment groups. Maximum generated pressure
was significantly higher for both FIB 10 and FIB 20 groups
when compared with IC.
DISCUSSION
In this study, we demonstrate a robust vasculogenic
response to therapy with construct-encapsulating EPCs.
We witnessed a high rate of cell migration from the
construct to the underlying ischemic myocardium. More-
over, there was a marked increase in vasculogenesis with
prolonged exposure of EPCs to ischemic myocardium at a
high concentration. This enhanced vasculogenesis appears
to have contributed to reduced myocardial scar and likely
subsequent preservation of myocardial structure and func-
tion. Over the past decade, numerous clinical trials have at-
tempted to use cell injection techniques, whether it be direct
myocardial injection, endocardial catheter–based injection,
or intracoronary delivery. None of these techniques have
demonstrated a clinically significant benefit that would suc-
cessfully affect long-term survival.18-26 Novel tissue-
engineered therapies as outlined in this article may provide
the ability to overcome the limitations of cell dispersal and
engraftment that have thus far limited clinical trials
exploring cell therapy.
Hydrogels have the unique ability to slowly degrade, in a
controlled fashion, and therefore provide a continuous and
long-term exposure of cytokines or cell therapy to the
myocardium.27,28 It is important to ensure that the desireddiovascular Surgery c Volume 148, Number 3 1095
TABLE 3. Left ventricular function assessed 4 weeks after left anterior descending ligation and treatment
Control
(n ¼ 10) IC (n ¼ 6) FIB 10 (n ¼ 9) FIB 20 (n ¼ 11)
10 mg/mL fibrin
with 7 3 106
EPCs/mL (n ¼ 9)
10 mg/mL fibrin
with 17 3 106
EPCs/mL (n ¼ 7)
20 mg/mL
fibrin with 7 3 106
EPCs/mL (n ¼ 10)
20 mg/mL fibrin
with 17 3 106
EPCs/mL (n ¼ 12)
CO (mL/min) 24.5  5.4 22.6  4.7 25.4  10.8 (P ¼ .6) 21.0  13.1 (P ¼ .8) 30.5  2.0 (P ¼ .006) 33.7  3.5 (P ¼ .001) 33.7  6.8 (P ¼ .01) 32.5  4.9 (P ¼ .006)
EF (%) 39.7  14.2 39.8  12.2 44.8  15.6 (P ¼ .6) 41.4  21.8 (P ¼ .9) 66.3  8.2 (P ¼ .0006) 68.8  10.7 (P ¼ .007) 69.7  6.4 (P ¼ .00002) 61.7  13.8 (P ¼ .0009)
Maximum
pressure
(mm Hg)
62.7  14.5 63.6  9.4 88.2  8.7 (P ¼ .001) 84.2  16.8 (P ¼ .02) 106.2  15.4 (P ¼ .0006) 109.1  23.3 (P ¼ .007) 101.8  13.7 (P ¼ .0001) 107.9  20.4 (P ¼ .002)
Contractility
(mL/mm Hg)
0.57  0.14 0.88  0.21 1.01  0.24 (P ¼ .5) 1.08  0.48 (P ¼ .5) 2.23  1.05 (P ¼ .03) 1.77  0.24 (P ¼ .008) 2.32  0.67 (P ¼ .005) 2.50  0.82 (P ¼ .005)
dP/dt max
(mm Hg/sec)
2156  677 2691  554 3880  758 (P ¼ .01) 3728  1185 (P ¼ .06) 5011  1281 (P ¼ .008) 5090  1257 (P ¼ .002) 6686  2587 (P ¼ .03) 5970  1661 (P ¼ .004)
Cardiac output was quantified using an ascending aortic flow probe; ejection fraction was measured with transthoracic echocardiography; and maximum pressure, contractility,
and dPdt were measured with an intraventricular pressure-volume catheter. P values are in relation to IC. CO, Cardiac output; EF, ejection fraction; EPC, endothelial progenitor
cell; IC, injection of EPCs; FIB, fibrin patch without cells.
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appropriate cell migration and differentiation.29 Cell den-
sity, adhesive ligands, and gel stiffness intrinsic to the
gels can dramatically alter stem cell fate; thus, it is vital
to carefully control these factors to maximize stem cell po-
tential.30 On the basis of our in vitro analysis, we found 10
mg/mL and 20 mg/mL gels to have desirable stiffness to
allow cell sprouting and spreading. In addition, this density
seemed to allow maximum cell migration. As was evident
in this study, no significant differences in vasculogenesis
or hemodynamics were present between 7 and 17 million
EPCs/mL cell densities.
Fibrin is desirable for cell-delivery applications given its
inherent biocompatibility and ability to maintain encapsu-
lated cell viability.31,32 In addition, tissue-engineered EPC
fibrin constructs as used in this study easily can be trans-
lated to the clinical arena, given preexistent Food and
Drug Administration approval. In fact, fibrin sealant and
glues are widely used in cardiac surgery and other surgical
specialties for hemostatic applications. Moreover, fibrin has
been studied for its intrinsic angiogenic abilities.33 Previous
studies have demonstrated a statistically significant increase
in myocardial angiogenesis and endothelialization.34-36
Likewise, we have demonstrated the intrinsic angiogenic
capabilities of fibrin in our studies when compared with
control. This intrinsic angiogenic potential may explain
the enhanced vasculogenesis and diminished fibrosis
that we witnessed with both FIB 10 and FIB 20 groups in
this study. This angiogenic capability likely further
complements the vasculogenesis and improved function
we have noticed in this study with EPC fibrin constructs,
thereby maximizing vasculogenic response beyond that of
the delivered EPCs with the constructs.
Tissue engineering, as used in this study, may provide the
ability to overcome the limitations that we have witnessed
over the past decade with cell-based therapies. These novel
approaches may allow investigators to enhance the delivery
of desired cells, use multiple cell types, incorporate
concomitant cytokine therapy, and provide gel-mediated
myocardial stabilization. Intricate tissue-engineered cell-
delivery strategies, as exemplified in this study, may provide1096 The Journal of Thoracic and Cardiovascular Surthe robust clinical response needed to normalize myocardial
function.CONCLUSIONS
We present a novel tissue-engineered, hydrogel-based,
EPC-mediated therapy to enhance cell delivery, cell retention,
vasculogenesis, and preservation of myocardial structure and
function. This therapeutic strategy may provide the ability to
overcome the limitations of cell dispersal and engraftment
associated with prior cell-based clinical therapies.References
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Dr Elaine Tseng (San Francisco, Calif). You’ve elegantly pre-
sented that EPCs embedded within a fibrin matrix hydrogel after
acute myocardial infarction increased vasculogenesis and
improved cardiac contractility. Stem cells have held significant
promise for the regeneration of cardiac myocardium but have
been fraught with difficulty in cell survival and retention for its
paracrine effects and arrhythmias from direct myocardial injec-
tion. This study is notable for demonstrating the ability of endothe-
lial progenitor stem cells to migrate from the hydrogel into the
injured myocardium after external patch placement of the biocom-
patible matrix.
Previously, not only various types of stem cells but also growth
factors and matrix materials have been investigated. Can you
comment on what might be the ideal combination for use in clin-
ical trials, as your group has investigated these other growth factors
and matrix components.
How do you envision bench-to-bedside translation and for what
population of patients? For example, in this study myocardial
infarction was acute, and this would require some requisite time
for cell and matrix generation before operation versus chronic
heart failure for patients with prior myocardial infarction.
Dr Atluri. I don’t know that we have all the questions answered
in terms of what the optimal components would be. We’ve started
off looking at EPCs, but I do envision a construct that could incor-
porate multiple subcomponents (ie, cytokines, EPCs). I don’t
know that we even have the right phenotype for the EPC yet.
But this is a start, at least, to begin looking at the ability to retain
cells.
In terms of the timing, I think it would be dependent on the com-
ponents. So from a vasculogenic strategy, it clearly makes sense to
think of an acute intervention shortly after a myocardial infarction.
Of course, immediately after a myocardial infarction the cell envi-
ronment is fairly hostile given inflammation in the heart, so that
may provide us the time to isolate cells.
From a chronic standpoint, a vasculogenic strategy does not
make a lot of sense unless you want to preserve purely the border
zone, so I think a myogenic strategy may make sense on a more
chronic model. Of course, then we’re dealing with the problems
that have really plagued us over the last 10 years, which is incor-
poration of muscle or islands of muscle that may bediovascular Surgery c Volume 148, Number 3 1097
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Sarrhythmogenic and may not electrically communicate with the
rest of the myocardium itself.
Dr Todd Rosengart (Houston, Tex). Congratulations, it’s good
to see that your group is continuing to focus attention on the ques-
tion of how to improve delivery and retention of delivering exog-
enous cells to the myocardium.
You nicely include a live/dead cell assay, but I was surprised
that you were satisfied with a 50% nonliving cell rate. Having
that data, were you able to isolate those cells and discard them,
or were they included in the injectate?
I was surprised that your cell delivery alone without fibrin did
not result in much of an improvement over controls. I think your
group has previously shown that cells alone, although not ideal,
are still effective. So can you explain?
Dr Atluri. I was a little bit surprised by that data as well. I think
it goes along with some of the clinical findings that were seen in
terms of clinical therapies with isolated EPC therapy. We noticed
small benefits in hemodynamic function. Amajority of the benefits
have been seen from a functional standpoint.
Our group has really seen benefits with cytokine therapy. In
terms of isolated stem cell therapy, we’ve done mesenchymal
stem cells but not isolated EPCs, so we haven’t seen the benefit
with the isolated EPCs.
This is somewhat of a preliminary study.We’ve seen lots of ben-
efits in rodents that have not translated to the clinical arena, so the
next step is to go to a large animal.
I’ve spent a lot of time debating this with my collaborators, the
bioengineers. I don’t know what to make of the 50% viability at 10
days. I think the real analysis is in an in vivo setting rather than in
vitro. I was happy with viability up-front, to know that the fibrin
microenvironment was not hostile immediately to the cells them-
selves. I think the next step would be to look at viability within the
gel in the in vivo implanted model.
Dr Rosengart. So you did not isolate out?
Dr Atluri. I did not isolate out, no.
Dr Bo Yang (Ann Arbor, Mich). Your stem cells treating infarc-
tion has been done clinically by the group at the University of Flor-
ida. They showed good magnetic resonance imaging of the
repopulation of muscle cells, but they didn’t see any improvement
of the ejection fraction. I think that makes sense. Because if you
popularize that scar area, or infarcted area, with muscle cells
from stem cells you still have the ischemia. Your LAD is still1098 The Journal of Thoracic and Cardiovascular Surligated. You have no blood supply to the LAD territory; that’s
why there is no increase of ejection fraction. Your data showed sig-
nificant improvement of the heart function. Do you have an
explanation?
From the catheter system, there are load-independent parame-
ters for the contractility, such as PRA, end-systolic pressure-
volume relationship, and dP/dt versus VED. Why didn’t you
use those parameters instead of ejection fraction, which is a
load-dependent parameter?
Dr Atluri.Yes, we looked at our contractility at the slope of the
end-systolic pressure-volume relationship and tried to eliminate
our load dependence in that situation. I’d put more credibility in
our slope of contractility than I would our ejection fraction, which
is largely a qualitative assay anyways.
Dr Yang. I didn’t see your data or any difference between those
2 groups.
Dr Atluri. There was improved contractility among our 4 treat-
ment groups. There was no difference in contractility with a denser
gel or with more cells that were implanted.
DrYang.The LAD still ligated. Do you have an explanation for
this change of ejection fraction?
Dr Atluri. I think it’s because of the enhanced vasculature from
a microenvironment. You’re right, this is still inferential and it’s
actually a perfusion analysis, so that will be the next step.
Dr John Mayer (Boston, Mass). You didn’t tell us about how
thick the patch is. Could you tell us that?
Dr Atluri. I actually haven’t measured the patch. It’s usually
100 mL that we put onto the Vicryl mesh, so it’s a fairly thin patch.
That’s why I think it’s still a preliminary study because it allows us
to do this on a rodent, and you can still get diffusion nutrients. But
that’s the reason why I don’t think it’s going to be scalable in its
current form to a clinical setting.
Dr Mayer. I would ask you to think about the idea that maybe
what you’re doing is altering the postinfarct inflammatory process
by virtue of this intervention as opposed to necessarily doing
something about the vascular bed immediately. In Juan Melero-
Martin’s studies from our institution where he is creating vascular-
ized implants, it takes days for his Matrigel implants containing
EPCs and mesenchymal stem cells to form a vasculature that con-
nects to the host vasculature. I wonder if there isn’t an alternate
explanation besides just growing more blood vessels.
Dr Atluri. Thank you.gery c September 2014
